GENE Presents Study Involving 200,000 Participants at 2021 San Antonio Breast Cancer Symposium
Genetic Technologies Limited (NASDAQ: GENE) announced that Dr. Erika Spaeth will present at the 2021 San Antonio Breast Cancer Symposium. The company highlighted significant advancements in its geneType Breast Cancer Test, showing better discrimination and calibration compared to traditional models. The new study, which analyzed over 200,000 UK Biobank participants, utilized 313 SNPs to enhance the risk model. The test can effectively identify breast cancer risk in over 85% of women, promoting early detection and better patient outcomes.
- Improved discrimination and calibration of geneType Breast Cancer Test over traditional models.
- Study validated with over 200,000 participants, enhancing credibility.
- Test can identify breast cancer risk in over 85% of women.
- None.
MELBOURNE, Australia, Dec. 10, 2021 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease confirms that the Company’s Director of Clinical Affairs & Medical Education, Erika Spaeth, PhD will be presenting at 2021 San Antonio Breast Cancer Symposium.
- New geneType Breast Cancer Test showed improved discrimination and calibration over traditional clinical models
- Study included over 200,000 participants to validate the risk model with an expanded panel of 313 SNPs
- Poster Presentation highlights the ongoing development of geneType Breast Cancer Risk Test
- GeneType for Breast Cancer can identify risk in more than
85% of women. Note that only about15% of women with breast cancer have a family member with history of this disease*
GENE is pleased to announce the Company’s Director of Clinical Affairs & Medical Education, Erika Spaeth, PhD will be presenting data from a new study the Company has undertaken with an expanded panel of 313 SNPs as part GENE’s ongoing test development and improvement for its geneType Breast Cancer Test.
This work has formed part of a development program to further improve the performance of the geneType Breast Cancer Test. It has been established that the ability to efficiently stratify women at high risk of developing breast cancer can lead to improved risk-reduction measures and patient outcomes. GENE’s latest model demonstrated an improvement in calibration and discrimination in women at risk of developing sporadic, non-hereditary breast cancer from traditional models. The study used 200,009 active UK Biobank (UKB) members aged 40 to 69 who were genetically Caucasian, with SNP data for 313 breast cancer associated variants.
This work highlights GENE’s ongoing commitment to continually improve the performance of the Company’s geneType Beast Cancer Risk Test. Dr Spaeth commented, “General population risk assessment tests like our geneType Breast Cancer Risk Test can lead to the identification of more women who would benefit from clinical intervention and consequently improved patient outcomes. In addition, risk assessment tests like geneType promote breast cancer awareness, empower women to understand their own risk and ultimately enable them to be part of the decision-making discussions with their healthcare providers.”
Source = *American Cancer Society: https://www.cancer.org/cancer/breast-cancer/risk-and-prevention/breast-cancer-risk-factors-you-cannot-change.html
| Investor Relations (Australia) | Investor Relations and Media (US) |
| Stephanie Ottens | Dave Gentry |
| Market Eye | 1 800 RED CHIP (733 2447) |
| M: +61 434 405 400 | Cell: 407 491 4498 |
| E: stephanie.ottens@marketeye.com.au | E: dave@redchip.com |
About Genetic Technologies Limited
Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”) is a diversified molecular diagnostics company. GENE offers cancer predictive testing and assessment tools to help physicians proactively manage patient health. The Company’s lead products GeneType for Breast Cancer for non-hereditary breast cancer and GeneType for Colorectal Cancer are clinically validated risk assessment tests and are first in class. Genetic Technologies is developing a pipeline of risk assessment products including its multi test covering over
For more information, please visit www.genetype.com
Forward-Looking Statements
This press release may contain forward-looking statements about the Company's expectations, beliefs or intentions regarding, among other things, statements regarding the expected use of proceeds. In addition, from time to time, the Company or its representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as "believe," "expect," "intend," "plan," "may," "should" or "anticipate" or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various filings made by the Company with the U.S. Securities and Exchange Commission, press releases or oral statements made by or with the approval of one of the Company's authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause the Company's actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause the Company's actual activities or results to differ materially from the activities and results anticipated in such forward-looking statements as detailed in the Company's filings with the Securities and Exchange Commission and in its periodic filings in Australia and the risks and risk factors included therein. In addition, the Company operates in an industry sector where securities values are highly volatile and may be influenced by economic and other factors beyond its control. The Company does not undertake any obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
FAQ
What improvements were made in the geneType Breast Cancer Test by GENE?
How many participants were involved in the study for the geneType Breast Cancer Test?
What is the significance of the expanded panel of SNPs in GENE's study?
When will Dr. Erika Spaeth present the findings related to the geneType Breast Cancer Test?
What percentage of women can the geneType Breast Cancer Test identify as being at risk?
